Department of Women's and Children's Health, Uppsala University Hospital, Akademiska Sjukhuset, SE-751 85 Uppsala, Sweden.
Oncol Rep. 2012 Mar;27(3):741-7. doi: 10.3892/or.2011.1578. Epub 2011 Dec 6.
The objective of this study was to evaluate the prognostic effect of the apoptosis regulators p53, bax and PUMA for recurrent disease and disease-free survival (DFS) in a series of 105 patients in FIGO-stages I-II with epithelial ovarian cancer, all treated with post-surgical platinum-taxane chemotherapy. For the detection of positivity of the biological markers p53, bax and PUMA the techniques of tissue microarrays and immunohistochemistry (IHC) were used. In tumors the frequency of p53 positivity was 24%, that of bax positivity was 83%, and strong positivity was found for PUMA (43%). The bax status was related to tumor grade (P=0.029). Positive staining for bax was related to strong positivity of PUMA in the tumors (P=0.004). The p53, bax or PUMA status alone or concomitant (p53 bax, p53 PUMA and bax PUMA) were not related to age, histopathological subtype, serous/non-serous tumors or type of the staging procedure at primary surgery. In survival analysis p53-positive tumors (P=0.014) and concomitant p53-positive and weak PUMA-positive tumors (P=0.015) were significantly correlated with shorter DFS. Concomitant p53-negative and bax-positive tumors were significantly correlated with longer survival (P=0.019). FIGO-stage (OR=6.0) and p53 status (OR=4.1) were predictive factors for tumor recurrence in logistic regression analysis and independent prognostic factors (HR=2.4 for both) in multivariate Cox regression analysis. In a separate Cox multivariate regression analysis the p53 bax status (HR=2.2) was an independent prognostic factor for DFS. The p53 PUMA status (HR=0.4) was not an independent prognostic factor, however, a borderline significance (P=0.07) was noted. Our results indicate that FIGO stage and p53 status alone were independent predictive factors for recurrence and prognostic factors for survival. Furthermore, p53 bax status was an independent prognostic factor for survival in this study.
本研究旨在评估凋亡调节因子 p53、bax 和 PUMA 在接受手术后铂类-紫杉烷化疗的 105 例 FIGO 分期 I-II 上皮性卵巢癌患者中对复发疾病和无病生存(DFS)的预后影响。为了检测生物标志物 p53、bax 和 PUMA 的阳性率,使用了组织微阵列和免疫组织化学(IHC)技术。在肿瘤中,p53 阳性率为 24%,bax 阳性率为 83%,PUMA 呈强阳性(43%)。bax 状态与肿瘤分级相关(P=0.029)。肿瘤中 bax 的阳性染色与 PUMA 的强阳性相关(P=0.004)。p53、bax 或 PUMA 状态单独或同时(p53 bax、p53 PUMA 和 bax PUMA)与年龄、组织病理学亚型、浆液性/非浆液性肿瘤或原发性手术时的分期程序类型无关。在生存分析中,p53 阳性肿瘤(P=0.014)和同时 p53 阳性和弱 PUMA 阳性肿瘤(P=0.015)与较短的 DFS 显著相关。同时 p53 阴性和 bax 阳性肿瘤与较长的生存时间显著相关(P=0.019)。FIGO 分期(OR=6.0)和 p53 状态(OR=4.1)是逻辑回归分析中肿瘤复发的预测因素,也是多变量 Cox 回归分析中的独立预后因素(HR 分别为 2.4)。在单独的 Cox 多变量回归分析中,p53 bax 状态(HR=2.2)是 DFS 的独立预后因素。p53 PUMA 状态(HR=0.4)不是独立的预后因素,但具有边缘显著性(P=0.07)。我们的结果表明,FIGO 分期和 p53 状态单独是复发的独立预测因素,也是生存的预后因素。此外,在本研究中,p53 bax 状态是生存的独立预后因素。